|
1
|
Goodenberger ML and Jenkins RB: Genetics
of adult glioma. Cancer Genet. 205:613–621. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cuddapah VA, Robel S, Watkins S and
Sontheimer H: A neuro-centric perspective on glioma invasion. Nat
Rev Neurosci. 15:455–465. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Franceschi E, Tosoni A, Girardi F and
Brandes AA: Bevacizumab in brain tumors: Ready for primetime.
Future Oncol. 5:1183–1184. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yu Z, Zhao G, Zhang Z, Li Y, Chen Y, Wang
N, Zhao Z and Xie G: Efficacy and safety of bevacizumab for the
treatment of glioblastoma. Exp Ther Med. 11:371–380. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hou LC, Veeravagu A, Hsu AR and Tse VC:
Recurrent glioblastoma multiforme: A review of natural history and
management options. Neurosurg Focus. 20:E52006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Coussens LM, Fingleton B and Matrisian LM:
Matrix metalloproteinase inhibitors and cancer: Trials and
tribulations. Science. 295:2387–2392. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fidler IJ, Kim SJ and Langley RR: The role
of the organ micro-environment in the biology and therapy of cancer
metastasis. J Cell Biochem. 101:927–936. 2007. View Article : Google Scholar
|
|
8
|
Stetler-Stevenson WG: Dynamics of matrix
turnover during pathologic remodeling of the extracellular matrix.
Am J Pathol. 148:1345–1350. 1996.PubMed/NCBI
|
|
9
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: Regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Figueira RC, Gomes LR, Neto JS, Silva FC,
Silva ID and Sogayar MC: Correlation between MMPs and their
inhibitors in breast cancer tumor tissue specimens and in cell
lines with different metastatic potential. BMC Cancer. 9:202009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shimoda M, Jackson HW and Khokha R: Tumor
suppression by stromal TIMPs. Mol Cell Oncol. 3:e9750822016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Groblewska M, Siewko M, Mroczko B and
Szmitkowski M: The role of matrix metalloproteinases (MMPs) and
their inhibitors (TIMPs) in the development of esophageal cancer.
Folia Histochem Cytobiol. 50:12–19. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
DeBin JA and Strichartz GR: Chloride
channel inhibition by the venom of the scorpion Leiurus
quinquestriatus. Toxicon. 29:1403–1408. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lyons SA, O'Neal J and Sontheimer H:
Chlorotoxin, a scorpion-derived peptide, specifically binds to
gliomas and tumors of neuroectodermal origin. Glia. 39:162–173.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Deshane J, Garner CC and Sontheimer H:
Chlorotoxin inhibits glioma cell invasion via matrix
metalloproteinase-2. J Biol Chem. 278:4135–4144. 2003. View Article : Google Scholar
|
|
16
|
Soroceanu L, Gillespie Y, Khazaeli MB and
Sontheimer H: Use of chlorotoxin for targeting of primary brain
tumors. Cancer Res. 58:4871–4879. 1998.PubMed/NCBI
|
|
17
|
Hockaday DC, Shen S, Fiveash J,
Raubitschek A, Colcher D, Liu A, Alvarez V and Mamelak AN: Imaging
glioma extent with 131I-TM-601. J Nucl Med. 46:580–586.
2005.PubMed/NCBI
|
|
18
|
Shen S, Khazaeli M, Gillespie GY and
Alvarez VL: Radiation dosimetry of 131I-chlorotoxin for
targeted radiotherapy in glioma-bearing mice. J Neurooncol.
71:113–119. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mamelak AN, Rosenfeld S, Bucholz R,
Raubitschek A, Nabors LB, Fiveash JB, Shen S, Khazaeli MB, Colcher
D, Liu A, et al: Phase I single-dose study of
intracavitary-administered iodine-131-TM-601 in adults with
recurrent high-grade glioma. J Clin Oncol. 24:3644–3650. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cheng YJ, Zhao JH, Qiao WL and Chen K:
Recent advances in diagnosis and treatment of gliomas using
chlorotoxin-based bioconjugates. Am J Nucl Med Mol Imaging.
4:385–405. 2014.PubMed/NCBI
|
|
21
|
Fan S, Sun Z, Jiang D, Dai C, Ma Y, Zhao
Z, Liu H, Wu Y, Cao Z and Li W: BmKCT toxin inhibits glioma
proliferation and tumor metastasis. Cancer Lett. 291:158–166. 2010.
View Article : Google Scholar
|
|
22
|
Zhao JH, Qiao WL, Zhang Y and Shao X:
Preparation and in vitro evaluation of 131I-BmK CT as a
glioma-targeted agent. Cancer Biother Radiopharm. 25:353–359. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qiao WL, Zhao JH, Shao X, Zhang Z, Liu X,
Wang T, Jin W and Yao Y: Preparation of 131I-BmK CT and
bio-distribution and imaging in glioma-bearing rats. Nucl Tech.
34:213–216. 2011.
|
|
24
|
Fu YJ, Yin LT, Liang AH, Zhang CF, Wang W,
Chai BF, Yang JY and Fan XJ: Therapeutic potential of
chlorotoxin-like neurotoxin from the Chinese scorpion for human
gliomas. Neurosci Lett. 412:62–67. 2007. View Article : Google Scholar
|
|
25
|
Fu YJ, An N, Chan KG, Wu YB, Zheng SH and
Liang AH: A model of BmK CT in inhibiting glioma cell migration via
matrix metalloproteinase-2 from experimental and molecular dynamics
simulation study. Biotechnol Lett. 33:1309–1317. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Steeg PS: Tumor metastasis: Mechanistic
insights and clinical challenges. Nat Med. 12:895–904. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mignatti P and Rifkin DB: Biology and
biochemistry of proteinases in tumor invasion. Physiol Rev.
73:161–195. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sternlicht MD and Werb Z: How matrix
metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol.
17:463–516. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim SK, Kang SW, Park HJ, Ban JY, Oh CH,
Chung JH, Oh IH, Cho KB and Park MS: Meta-analysis of association
of the matrix metalloproteinase 2 (-735 C/T) polymorphism with
cancer risk. Int J Clin Exp Med. 8:17096–17101. 2015.
|
|
30
|
Schulz R: Intracellular targets of matrix
metalloproteinase-2 in cardiac disease: Rationale and therapeutic
approaches. Annu Rev Pharmacol Toxicol. 47:211–242. 2007.
View Article : Google Scholar
|
|
31
|
Valente P, Fassina G, Melchiori A,
Masiello L, Cilli M, Vacca A, Onisto M, Santi L, Stetler-Stevenson
WG and Albini A: TIMP-2 over-expression reduces invasion and
angiogenesis and protects B16F10 melanoma cells from apoptosis. Int
J Cancer. 75:246–253. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Su Y, Wan D and Song W: Dryofragin
inhibits the migration and invasion of human osteosarcoma U2OS
cells by suppressing MMP-2/9 and elevating TIMP-1/2 through
PI3K/AKT and p38 MAPK signaling pathways. Anticancer Drugs.
27:660–668. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Schlumberger M, Catargi B, Borget I,
Deandreis D, Zerdoud S, Bridji B, Bardet S, Leenhardt L, Bastie D,
Schvartz C, et al: Strategies of radioiodine ablation in patients
with low-risk thyroid cancer. N Engl J Med. 366:1663–1673. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gruenwald F and Ezziddin S:
131I-Metaiodobenzylguanidine therapy of neuroblastoma
and other neuroendocrine tumors. Semin Nucl Med. 40:153–163. 2010.
View Article : Google Scholar
|
|
35
|
Klutz K, Schaffert D, Willhauck MJ,
Gruenwald GK, Haase R, Wunderlich N, Zach C, Gildehaus FJ,
Senekowitsch-Schmidtke R, Goeke B, et al: Epidermal growth factor
receptor-targeted 131I-therapy of liver cancer following
systemic delivery of the sodium iodide symporter gene. Mol Ther.
19:676–685. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kayano D and Kinuya S: Current consensus
on I-131 MIBG therapy. Nucl Med Mol Imaging. 52:254–265. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sgouros G, Kolbert KS, Sheikh A, Pentlow
KS, Mun EF, Barth A, Robbins RJ and Larson SM: Patient-specific
dosimetry for 131I thyroid cancer therapy using
124I PET and 3- dimensional-internal dosimetry (3D-ID)
software. J Nucl Med. 45:1366–1372. 2004.PubMed/NCBI
|
|
38
|
Zhang X, Liu DS, Luan ZS, Zhang F, Liu XH,
Zhou W, Zhong SF and Lai H: Efficacy of radioiodine therapy for
treating 20 patients with pulmonary metastases from differentiated
thyroid cancer and a meta-analysis of the current literature. Clin
Transl Oncol. 20:928–935. 2018. View Article : Google Scholar :
|
|
39
|
Hosseinimehr SJ: Flavonoids and genomic
instability induced by ionizing radiation. Drug Discov Today.
15:907–18. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Leo M, Sabini E, Ionni I, Sframeli A,
Mazzi B, Menconi F, Molinaro E, Bianchi F, Brozzi F, Santini P, et
al: Use of low-dose radioiodine ablation for Graves' orbitopathy:
Results of a pilot, perspective study in a small series of
patients. J Endocrinol Invest. 41:357–361. 2018. View Article : Google Scholar
|
|
41
|
Spanu A, Solinas ME, Chessa F, Sanna D,
Nuvoli S and Madeddu G: 131I SPECT/CT in the follow-up
of differentiated thyroid carcinoma: Incremental value versus
planar imaging. J Nucl Med. 50:184–90. 2009. View Article : Google Scholar : PubMed/NCBI
|
